Abstract
We investigated the prevalence and epidemiology of AmpC plasmidic cephalosporinases in Escherichia coli clinical strains resistant to third-generation cephalosporins during a 5-year period at Nantes University Hospital, France (3100 beds). The prevalence and diversity of plasmidic cephalosporinase did not increase during the study period (0.09% of 25 861 E. coli isolates); only CMY-2 producers were detected (and 1 new variant, with a Y-to-C substitution at position 219). CMY-2-producing strains belonged to the 4 main phylogenetic groups and to 11 different sequence types. Three sequence types included more than 1 isolate (ST156, ST46, and ST354).
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / pharmacology
-
Bacterial Proteins / biosynthesis*
-
Bacterial Typing Techniques
-
Cephalosporins / pharmacology
-
Cluster Analysis
-
DNA Fingerprinting
-
DNA, Bacterial / chemistry
-
DNA, Bacterial / genetics
-
Escherichia coli / classification*
-
Escherichia coli / enzymology*
-
Escherichia coli / isolation & purification
-
Escherichia coli Infections / epidemiology*
-
Escherichia coli Infections / microbiology
-
France / epidemiology
-
Genotype
-
Hospitals, Teaching
-
Humans
-
Plasmids*
-
Prevalence
-
Sequence Analysis, DNA
-
beta-Lactam Resistance
-
beta-Lactamases / biosynthesis*
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
Cephalosporins
-
DNA, Bacterial
-
AmpC beta-lactamases
-
beta-Lactamases